Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Hanmi Pharmaceutical Company Limited
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07449754CT.gov Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma | — | Recruiting | — | — | — |
NCT05611229CT.gov Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden | — | Completed | — | — | — |
NCT04109456CT.gov IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma | — | Completed | — | — | — |
NCT03625141CT.gov A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases | — | Completed | — | — | — |
NCT03175432CT.gov Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases | — | Active Not Recruiting | — | — | — |
NCT02768207CT.gov A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma | — | Completed | — | — | — |
NCT02230306CT.gov Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases | — | Terminated | — | — | — |
NCT02414750CT.gov Vemurafenib Plus Cobimetinib in Metastatic Melanoma | — | Terminated | — | — | — |
NCT01876641CT.gov Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib | — | Terminated | — | — | — |
NCT01495988CT.gov Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cobimetinib (this asset) | Hanmi Pharmaceutical Company Limited | P2 | B · 58 |
| Cediranib | M.D. Anderson Cancer Center | P2 | BBB |
| Dacarbazine | Shanghai Junshi Bioscience Co., Ltd. | P4 | BBB |
| Ifa | Craig L Slingluff, Jr | P2 | BB |
| Nivolumab | Bristol-Myers Squibb | P4 | BB |
| Therapeutic Autologous Lymphocytes | Fred Hutchinson Cancer Center | P2 | BB |
| TIL | East Metropolitan Health Service, Australia | P2 | BB |
| Montanide Isa 51 | Ludwig Institute for Cancer Research | P2 | BB |
| Ipilimumab | NYU Langone Health | P4 | BB |
+42 more in the Metastatic Melanoma cohort
Other indications for Cobimetinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Malignant Pancreatic Neoplasm | — | P2 | B · 62 |
| Melanoma | — | P3 | B · 62 |
| Hematopoietic And Lymphoid System Neoplasm | — | P2/3 | B · 62 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cobimetinib in Metastatic Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cobimetinib-metastatic-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →